The impact of COVID-19 on medication reviews in English primary care. An OpenSAFELY-TPP analysis of 20 million adult electronic health records.
null nullChristopher WoodVictoria SpeedLouis FisherHelen J CurtisAndrea L SchafferAlex J WalkerRichard CrokerAndrew D BrownChristine CunninghamWilliam J HulmeColm D AndrewsBen F C Butler-ColeDavid EvansPeter InglesbyIain DillinghamSebastian C J BaconSimon DavyTom WardGeorge HickmanLucy BridgesThomas O'DwyerSteven MaudeRebecca M SmithAmir MehrkarChristopher BatesJonathan CockburnJohn ParryFrank HesterSam HarperAlex J WalkerBrian MackennaPublished in: British journal of clinical pharmacology (2024)
There was a substantial reduction in the monthly rate of medication reviews during the pandemic but rates recovered by the end of the study period. Structured medication reviews were prioritized for high-risk patients.
Keyphrases
- electronic health record
- adverse drug
- coronavirus disease
- primary care
- sars cov
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- clinical decision support
- randomized controlled trial
- systematic review
- meta analyses
- general practice
- respiratory syndrome coronavirus